A long-term study of DSP-5423 in pediatric patients with schizophrenia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221683

Enrollment

150

Registered

2011-12-28

Start date

2012-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : DSP-5423 (blonanserin) INN of investigational material : Blonanserin Therapeutic category code : 117 Psychotropic agents Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who completed the confirmatory study etc.

Exclusion criteria

Exclusion criteria: Patients who fall under a contraindication listed in the LONASEN package insert. Patients with Parkinson disease etc.

Design outcomes

Primary

Measure	Time frame
safety Adverse events (AEs) Frequency of AE or treatment-related AEs	—

Secondary

Measure	Time frame
efficacy PANSS total score change at Final visit	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026